Beyond drugs: Non-invasive focused ultrasound brain stimulation as a novel intervention for mental health

Lead Research Organisation: University of Nottingham
Department Name: School of Medicine

Abstract

Drugs are horrible. While many psychiatric and neurological conditions are treated with pharmaceutical drugs, side effects remain severe. As one sufferer of epilepsy commented: "If the side effects of anti-epileptic drugs would be considered on their own, they would be an own disease category". Drugs, once passing through the blood-brain-barrier, affect the entire brain and its effect is not just limited to the regions that are linked to brain network disorders. Even worse, often the drugs don't work. For a third of epilepsy patients, drugs are ineffective in reducing the number of seizures, and for diseases such as dementia, there are no drugs with obvious benefits in humans. This situation is unlikely to improve as, for example, dementia clinical trials have failed, and more and more pharmaceutical companies are quitting brain disorder drug development altogether.

Brain stimulation of distinct regions of the brain offers a potential route to new treatments. However, the effects are often inconsistent between patients and, in particular for older subjects, invasive approaches using implants are seen as risky by clinicians. Therefore, for neuromodulation to replace drugs in the future, interventions need to be personalised and non-invasive. The solution to replace pharmaceutical drugs for many brain disorders before 2050 is the proposed development of an approach that is (a) non-invasive through using focused ultrasound stimulation and (b) personalised through using computer models to predict which network nodes or edges should be targeted and which stimulation protocol should be used.

Enabled by this proof of concept, computer simulations can test thousands of different stimulation approaches before deciding on an optimal approach for an individual patient. This is crucial, as trial-and-error in human patients is not an option. For deep-brain stimulation in Parkinson's disease, the fine-tuning of the stimulation algorithm for each patient takes several weeks. Whereas this is tuning the protocol alone, the situation will be more challenging when also the target structure needs to be determined. Phase 1 will show whether predicting stimulation outcomes is feasible and will therefore de-risk the healthcare implementation in phase 2.
 
Description While neurotechnology provides opportunities for novel mental health interventions, preferences of patients and the general public, and the reasons for their choices are still unclear. Here, we conducted a large-scale online survey with 784 participants, half of them suffering from psychiatric and/or neurological conditions. We asked about techniques ranging from invasive (pharmaceutical drugs and brain implants) to noninvasive approaches (ultrasound, magnetic, or electric stimulation). First, participants had a low level of prior knowledge but were interested and excited about these opportunities. Second, both patients and the general population preferred focused ultrasound stimulation (first choice) while drugs and implants were ranked 3rd and 5th out of five, respectively. Finally, that preference was mainly driven by whether they perceived a technology as safe, rather than as effective. Overall, this survey identifies safety as main criterion for interventions and shows a preference for novel noninvasive approaches such as focused ultrasound neuromodulation.
Exploitation Route This survey highlights preferences of current and future consumers of healthcare neurotechnology and might influence future research and development in the field.
Sectors Digital/Communication/Information Technologies (including Software)

Electronics

Healthcare

URL https://doi.org/10.1101/2024.01.10.24301043
 
Description DeepBrain: A novel human brain interface that non-invasively writes using focused ultrasound
Amount £200,781 (GBP)
Funding ID EP/X01925X/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2022 
End 03/2024